Raman spectroscopy and machine learning have become popular in in-line monitoring of bioreactors. However, traditional modeling processes typically entail extensive fermentation batches to collect learning datasets, which are significantly time-consuming and laborious. In addition, these models are limited to configurations with the same conditions as the training batches. The present work proposes a reproducible and adaptable modeling approach by combining standard spectra as a training dataset, with a simple means of correcting for cell scattering. Alcoholic fermentation by Saccharomyces cerevisiae is used as a benchmark. Initially, a partial least squares (PLS) regression model was developed based on the spectra of pure solutions of glucose and ethanol. Then, a mathematical expression was defined to estimate yeast concentration, allowing the correction of Raman intensity attenuated by cell scattering. The corrected spectra demonstrate close alignment with reference spectra in both shape and intensity. Validation of the methodology was conducted across numerous batches and one fed-batch bioreactor. As a result, the developed method enables the simultaneous monitoring of glucose, ethanol, and yeast concentrations, effectively addressing the challenge of implementing an independent standards based PLS model to manage the intricate compositional dynamics in bio-processes. The conclusion underscores the effectiveness of the proposed method and offers new prospects in biotechnological industries.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jbiotec.2024.10.007 | DOI Listing |
Alzheimers Dement
December 2024
Department of Bioengineering, University of California, Los Angeles, CA, USA, Los Angeles, CA, USA.
Background: The initiation of amyloid plaque deposition signifies a crucial stage in Alzheimer's disease (AD) progression, which often coincides with the disruption of neural circuits and cognitive decline. While the role of excitatory-inhibitory balance is increasingly recognized in AD pathophysiology, targeted therapies to modulate this balance remain underexplored. This study investigates the effect of perampanel, a selective non-competitive AMPA receptor antagonist, in modulating neurophysiological changes in hAPP-J20 transgenic Alzheimer's mice.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Odessa National Maritime University, Odessa, Ukraine.
Background: Alzheimer's disease can cause sleep disturbances in humans, which can worsen other symptoms of the disease.
Method: In our study, we examined the sleep patterns of 23 patients with Alzheimer's disease, aged 65-74 years (20 women and 3 men), over 4 months. All patients reported experiencing poor sleep, including difficulty sleeping in the ward, frequent awakenings during the night, early morning awakenings, and daytime sleepiness.
Alzheimers Dement
December 2024
Milano Bicocca University, Milan, Lombardia Region, Italy.
Background: Nonpharmacological approaches have been identified as first line treatments for the behavioral and psychological symptoms (NPS) of persons living with dementia (PLWD).
Methods: This is a single-arm study to evaluate the feasibility of the TAP approach to promote continuity of care between hospital (S. Gerardo hospital - Italy) and community.
Eur J Neurosci
January 2025
Department of Biology, Concordia University, Montreal, QC, Canada.
Through the lens of preclinical research on substance use disorders (SUD), I propose a reflection aimed at re-evaluating animal models in neuroscience, with a focus on ecological relevance. While rodent models have provided valuable insights into the neurobiology of SUD, the field currently faces a validation crisis, with findings often failing to translate into effective human treatments. Originally designed to address the lack of reproducibility in animal studies, the current global gold standard of rigorous standardization has led to increasingly controlled environments.
View Article and Find Full Text PDFDrugs Aging
January 2025
Department of Geriatric Medicine, Jeroen Bosch Hospital, 's Hertogenbosch, The Netherlands.
Purpose: Renin-angiotensin-aldosterone system inhibitors (RAASi) are widely used in treatment of cardiovascular and renal disease. While effective, they pose a risk of hyperkalemia. In the general population, risk factors for hyperkalemia include chronic kidney disease, congestive heart failure, and use of medication affecting potassium balance.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!